 |
| 삼성바이오로직스 인천 송도 공장 (사진=삼성바이오로직스) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Samsung BioLogics, South Korea's leading pharmaceutical and bio company, posted a record high in the first quarter of this year.
It is due to the increase in sales of raw materials and medicines. The company has fully operated its 1-3 plants, 4 plants have partially gone into operation and 5 plants are also scheduled to operate in 2 years.
Samsung BioLogics announced on the 24th that it recorded consolidated sales of 720.9 billion won and operating profit of 191.7 billion won in the first quarter of 2023. Due to stable growth of consigned production development (CDMO) business and consolidation of Samsung Bioepis (Epis) performance, sales increased by 41% (+209.6 billion won) and operating profit by 9% (+15.3 billion won) compared to the same period last year.
Samsung BioLogics' sales and operating profit both increased. The amount of revenue internal exchange was -83.5 billion won, and operating profit internal exchange and PPA amortization was -79 billion won.
Samsung Biologics recorded sales of 591 billion won and operating profit of 234.4 billion won in the first quarter. Sales and operating profit rose 16 percent and 33 percent, respectively, on-year, due to increased sales of raw material medicine (DS) and rising exchange rates. In particular, Samsung BioLogics explained that operating profit increased significantly as a result of maximizing operational efficiency by operating all of its 1-3 plants.
Samsung Bioepis recorded 213.4 billion won in sales and 36.1 billion won in operating profit in the first quarter.
Samsung BioLogics also raised its earnings forecast for this year as sales growth continued steadily and sales contributions from its four plants became visible.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
